Deltex Medical Group PLC Director Dealing (4527O)
February 09 2021 - 4:31AM
UK Regulatory
TIDMDEMG
RNS Number : 4527O
Deltex Medical Group PLC
09 February 2021
9 February 2021
Deltex Medical Group plc
("Deltex Medical" or the "Company")
Director Dealing
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring
("ODM"), announces that Andrew Mears, Chief Executive Officer of the Company, advised the
Company today that he has transferred 3,076,923 Ordinary Shares of 1p each in the Company
("Ordinary Shares") which he purchased in the subscription on 21 December 2020 into his Self-Invested
Personal Pension. His beneficial holding remains unchanged by this transaction.
For further information, please contact:-
Deltex Medical Group plc 01243 774 837
Andy Mears, CEO investorinfo@deltexmedical.com
David Moorhouse, Group Finance Director
Nominated Adviser & Broker
Arden Partners plc 020 7614 5900
Benjamin Cryer
Dan Gee-Summons
Joint Broker
Turner Pope Investments (TPI) Ltd 0203 657 0050
Andy Thacker info@turnerpope.com
Zoe Alexander
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies which are primarily
used in critical care and general surgical procedures. Deltex Medical's proprietary oesophageal
Doppler monitoring ("ODM") (TrueVue Doppler) measures blood flow velocity in the central circulation
in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates
a low-frequency ultrasound signal which is highly sensitive to changes in blood flow and measures
such changes in 'real time'. Deltex Medical is the only company in the enhanced haemodynamic
space to have built a robust and credible evidence base demonstrating both the clinical and
economic benefits of its core technology: TrueVue Doppler. This technology has been proven
in a wide range of clinical trials to reduce complications suffered by patients after surgery
and consequently can save hospitals money.
Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians
with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely
non-invasive monitoring technology which transmits low magnitude, high frequency electrical
signals through the thorax and measures the changes to this signal when the heart pumps blood.
TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information
on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically
stable patients.
Group goal
Haemodynamic management is now becoming widely accepted as a vital part of the anaesthesia
protocols for surgical patients, as well as treating ventilated intensive care patients, including
ventilated COVID-19 patients. Consequently, the Group's focus is on maximising value from
the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical
practice around the world. The Group aims to provide clinicians with a single platform - a
'haemodynamic workstation' - which offers them a range of technologies from simple to sophisticated
to be deployed according to the patient's clinical condition as well as the skill and expertise
of the user. Doing this will enable the Group to partner with healthcare providers to support
modern haemodynamic management across the whole hospital.
The Group is currently in the implementation phase of achieving this goal in a number of territories
worldwide, operating directly in the UK and the USA, and via agreements with approximately
40 distributors overseas.
Notification of transactions by Directors, Persons Discharging
Managerial Responsibilities ("PDMRs") and persons closely
associated with them.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Andrew Mears
-------------------------------- -----------------------------------------
2. Reason for the Notification
---------------------------------------------------------------------------
a) Position/status CEO
-------------------------------- -----------------------------------------
b) Initial notification/amendment Initial notification
-------------------------------- -----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Deltex Medical Group plc
-------------------------------- -----------------------------------------
b) LEI 213800XN34P6LI8J6M39
-------------------------------- -----------------------------------------
4. Details of the transaction(s):section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv)each place where transactions have been
conducted
---------------------------------------------------------------------------
a) Description of the Financial Ordinary Shares of 1 p each
instrument, type of instrument
-------------------------------- -----------------------------------------
Identification code GB0059337583
-------------------------------- -----------------------------------------
b) Nature of the Transaction Transfer into SIPP
-------------------------------- -----------------------------------------
c) Price(s) and volume(s) 3,076,923 Ordinary shares
-------------------------------- -----------------------------------------
d) Aggregated information
* Aggregated volume 3,076,923
1.3 pence
* Price
-------------------------------- -----------------------------------------
e) Date of the transaction 8 February 2021
-------------------------------- -----------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
-------------------------------- -----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFVIFIIAIIL
(END) Dow Jones Newswires
February 09, 2021 05:31 ET (10:31 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2023 to Apr 2024
